Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Atossa Therapeutics, Inc.

Market Cap 22.26M 19.32M 17.81M 16.68M 31.17M 2.13B 31.82M 212M 82.24M 1.03B 83.57M 81.76M 3.57B P/E Ratio 2026 *
-0.59x
P/E Ratio 2027 * -0.95x
Enterprise Value 22.26M 19.32M 17.81M 16.68M 31.17M 2.13B 31.82M 212M 82.24M 1.03B 83.57M 81.76M 3.57B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.87%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day-41.25%
1 week-46.70%
Current month-50.57%
1 month-53.00%
3 months-45.92%
6 months-80.95%
Current year-70.79%
1 week 2.52
Extreme 2.52
4.59
1 month 2.52
Extreme 2.52
5.31
Current year 2.52
Extreme 2.52
10.95
1 year 2.52
Extreme 2.52
19.35
3 years 2.52
Extreme 2.52
34.65
5 years 2.52
Extreme 2.52
147
10 years 2.52
Extreme 2.52
959.85
Manager TitleAgeSince
Chief Executive Officer 75 2009-03-31
Director of Finance/CFO 50 2025-10-13
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Chairman 75 2009-03-31
Director/Board Member 64 2009-03-31
Director/Board Member 79 2011-06-30
Date Insider Type Main position Quantity % Market Cap.
05-11Free

Director

10,000 0.1161%
05-11Free

Director

10,000 0.1161%
05-11
Ensisheim Partners LLC
OtherCompany 0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-41.25%-46.70%-80.37%-80.43% 37.89M
-1.40%+0.12%-14.73%-12.58% 43.68B
+3.50%-4.15%+265.85%+484.30% 30.65B
-0.61%-3.11%+14.00%-12.36% 30.4B
-1.27%-7.02%-0.82%+20.47% 29.31B
-0.66%-5.84%+7.59%+12.76% 24.2B
+2.01%+3.57%+57.15%+128.55% 13.3B
+2.77%-1.48% - - 13.03B
-1.65%-1.08%+7.92%+7.56% 13.21B
+0.68%-1.74%+103.98%+81.60% 12.12B
Average -3.79%-6.15%+40.06%+69.99% 20.99B
Weighted average by Cap. +0.11%-1.66%+51.87%+89.51%

Financials

2026 *2027 *
Net sales - -
Net income -38.34M -33.28M -30.67M -28.74M -53.7M -3.67B -54.82M -366M -142M -1.77B -144M -141M -6.15B -44.21M -38.37M -35.36M -33.14M -61.91M -4.23B -63.2M -422M -163M -2.04B -166M -162M -7.09B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
26-06-11 2.585 $ -41.25% 1,410,918
26-06-10 4.400 $ -0.23% 29,976
26-06-09 4.410 $ -3.08% 53,900
26-06-08 4.550 $ +1.79% 36,026
26-06-05 4.470 $ -7.84% 80,972
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.585USD
Average target price
22.75USD
Spread / Average Target
+780.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!